Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY Targets Unleashing Growth From Private Label Drag

This article was originally published in The Tan Sheet

Executive Summary

“Where we have opportunities to hold on to” private label business, “we'll hold on to it, but not at any cost,” says President and CEO Steve Cahillane. “Due to private label margins” becomes common refrain in NBTY’s income downturn.

You may also be interested in...



NBTY Cuts Its Losses, Leaving Contract Manufacturing

The supplement manufacturer and retailer says it will cease contract manufacturing as it increases its focus on growing its branded product and retail businesses, particularly internationally. Private label production continues but will become a smaller part of its business.

NBTY Cuts Its Losses, Leaving Contract Manufacturing

The supplement manufacturer and retailer says it will cease contract manufacturing as it increases its focus on growing its branded product and retail businesses, particularly internationally. Private label production continues but will become a smaller part of its business.

Private Label: A Riddle Wrapped In A Mystery Inside An Enigma For Major Supplement Manufacturers

GNC looks at restoring growth to its private label and contract manufacturing business and Vitamin Shoppe works on getting its business growing, but NBTY continues to lament the drag the segment is having on its overall growth.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel